AR062400A1 - Uso de derivados de 2,5-dihidroxibenceno para tratar queratosis actinica - Google Patents

Uso de derivados de 2,5-dihidroxibenceno para tratar queratosis actinica

Info

Publication number
AR062400A1
AR062400A1 ARP070103644A ARP070103644A AR062400A1 AR 062400 A1 AR062400 A1 AR 062400A1 AR P070103644 A ARP070103644 A AR P070103644A AR P070103644 A ARP070103644 A AR P070103644A AR 062400 A1 AR062400 A1 AR 062400A1
Authority
AR
Argentina
Prior art keywords
formula
cation
arylalkyl
compound
treatment
Prior art date
Application number
ARP070103644A
Other languages
English (en)
Inventor
Lopez Serafin Valverde
Sanchez Pedro Cuevas
Garrido Antonio Romero
Gallego Guillermo Gimenez
De Tejada Gorman Inigo Saenz
Puerto Rosa Maria Lozano
Frutos Javier Angulo
Original Assignee
Action Medicines Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38582009&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR062400(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from ES200602219A external-priority patent/ES2315119B1/es
Application filed by Action Medicines Sl filed Critical Action Medicines Sl
Publication of AR062400A1 publication Critical patent/AR062400A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/618—Salicylic acid; Derivatives thereof having the carboxyl group in position 1 esterified, e.g. salsalate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Transplantation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Reivindicacion 1: Uso de derivados 2,5-dihidroxibencénicos representados por la formula (1), en la cual R1en cada caso se selecciona de forma independiente como -OH o -OR2; Y es -SO3H, -SO3-.X+, -SO3R3, -PO3H, -PO3-.X+, -PO3R3, -CO2H, -CO2-.X+ o - CO2R3; X+ es un cation orgánico o inorgánico; R2 es un grupo alquilo bajo, arilo, arilalquilo, alquilsulfonilo, arilsulfonilo, alquilarilsulfonilo, arilalquilsulfonilo, ariloxialquilo, arilcarbonilo o arilcarbonilo; R3 es un grupo alquilo bajo, arilo, arilalquilo, o alquilarilo; a es un numero entero entre 0 y 6; El cation X+ en el compuesto de formula (1) puede ser cualquier cation fisiologicamente aceptable conocido en el estado de la técnica. El cation X es seleccionado de forma que la carga general de la formula (1) sea neutra. El compuesto de formula (1) es el 2,5-dihidroxibenceno sulfonico (Dobesilato) o el ácido gentísico o el ácido homogentísico o las sales o ésteres de éstos para la elaboracion de un fármaco, medicamento o compuesto destinado al tratamiento cosmético de la obesidad o de la adipogénesis excesiva, el tratamiento del hirsutismo y de la hipertricosis y tratamiento de las verrugas virales.
ARP070103644A 2006-08-16 2007-08-16 Uso de derivados de 2,5-dihidroxibenceno para tratar queratosis actinica AR062400A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200602219A ES2315119B1 (es) 2006-08-16 2006-08-16 Uso de derivados 2,5 -dihidroxibencenicos en la fabricacion de medicamentos y cosmeticos.
ES200701857 2007-07-02

Publications (1)

Publication Number Publication Date
AR062400A1 true AR062400A1 (es) 2008-11-05

Family

ID=38582009

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP070103645A AR062401A1 (es) 2006-08-16 2007-08-16 Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
ARP070103642A AR062398A1 (es) 2006-08-16 2007-08-16 Uso de derivados del 2,5-dihidroxibenceno para tratar obesidad, hirsutismo, hipertricosis y verrugas viricas
ARP070103644A AR062400A1 (es) 2006-08-16 2007-08-16 Uso de derivados de 2,5-dihidroxibenceno para tratar queratosis actinica

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP070103645A AR062401A1 (es) 2006-08-16 2007-08-16 Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
ARP070103642A AR062398A1 (es) 2006-08-16 2007-08-16 Uso de derivados del 2,5-dihidroxibenceno para tratar obesidad, hirsutismo, hipertricosis y verrugas viricas

Country Status (7)

Country Link
US (5) US20080114075A1 (es)
EP (2) EP2056815B1 (es)
AR (3) AR062401A1 (es)
CL (3) CL2007002381A1 (es)
ES (2) ES2409172T3 (es)
PT (2) PT2056815E (es)
WO (3) WO2008020025A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080125485A1 (en) * 2004-02-17 2008-05-29 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
ES2238924B1 (es) 2004-02-17 2006-12-01 Investread Europa, S.L. Uso del acido 2,5-dihidroxibencenosulfonico, en la fabricacion de medicamentos de aplicacion en el tratamiento de enfermedades angiodependientes.
US20070149618A1 (en) 2004-02-17 2007-06-28 Action Medicines, S.L. Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
US20080114075A1 (en) 2006-08-16 2008-05-15 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis
US8541467B2 (en) * 2006-08-16 2013-09-24 Action Medicines, S.L. Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ
US20110196040A1 (en) 2008-02-15 2011-08-11 Action Medicines S.L. Skin Penetration Enhancing Systems for Polar Drugs
CA2729767A1 (en) * 2008-07-07 2010-01-14 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same
US9251210B2 (en) * 2013-04-19 2016-02-02 Oracle International Corporation Caching external data sources for SQL processing
US10936616B2 (en) 2014-06-09 2021-03-02 Oracle International Corporation Storage-side scanning on non-natively formatted data
US10019473B2 (en) 2014-06-09 2018-07-10 Oracle International Corporation Accessing an external table in parallel to execute a query

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954767A (en) * 1972-05-17 1976-05-04 Esteve Subirana Antonio Piperazine salts of 2,5-dihydroxy benzene sulfonic acid mono- and diesters
US4115648A (en) * 1974-09-13 1978-09-19 Laboratorios Del Dr. Esteve, S.A. 2,5-Dihydroxy benzene sulfonic acid mono esters
US4137311A (en) * 1977-09-22 1979-01-30 William H. Rorer, Inc. Synergistic compositions and method of use
US4513007A (en) 1983-05-03 1985-04-23 Laboratoires Om Sa Method for treating heart disease
EP0204987B1 (de) 1985-05-15 1991-11-21 Roshdy Dr. Ismail Vitamin E-haltiges Mittel zur Verbesserung der Eigenschaften des Blutes
US4837378A (en) 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
GB8620073D0 (en) * 1986-08-18 1986-10-01 Delandale Lab Ltd Pharmaceutical compositions
DE4230262A1 (de) * 1992-09-10 1994-03-17 Behringwerke Ag Substituierte Phenole, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von zellproliferationsbedingten Erkrankungen
US5374772A (en) * 1992-12-08 1994-12-20 Hoffmann-Laroche Inc. Substituted benzoic acids, inhibitors of phospholipases A2
FR2717078B1 (fr) * 1994-03-08 1996-12-13 Oreal Utilisation des acides sulfoniques comme agents antivieillissement dans une composition cosmétique ou dermatologique.
WO1996017589A1 (en) 1994-12-08 1996-06-13 Kao Corporation Method of smoothing or removing wrinkles and method of stimulating collagen synthesis
US5610185A (en) 1995-02-17 1997-03-11 The United States Of America As Represented By The Department Of Health And Human Services Method for the treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein cross-linking compounds
JPH08283152A (ja) * 1995-04-12 1996-10-29 Kao Corp 細胞接着抑制剤
WO1999011255A1 (fr) * 1997-08-28 1999-03-11 Ono Pharmaceutical Co., Ltd. Regulateurs du recepteur active par les agents de proliferation des peroxysomes
FR2782269B1 (fr) * 1998-08-17 2001-08-31 Oreal Composition cosmetique et/ou dermatologique contenant de l'acide salicylique ou un derive d'acide salicylique et son utilisation
US6258821B1 (en) * 1999-04-26 2001-07-10 Medimmune Oncology, Inc. Compositions comprising trimetrexate and methods of their synthesis and use
US6787573B2 (en) * 1999-07-02 2004-09-07 Universiteit Utrecht Antiviral therapy
US20020037319A1 (en) * 1999-11-08 2002-03-28 Alan Drizen Drug preparations
GB9927629D0 (en) * 1999-11-24 2000-01-19 Croda Int Plc Compounds
US7312247B2 (en) * 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
WO2003016265A1 (fr) * 2001-08-17 2003-02-27 Eisai Co., Ltd. Compose cyclique et agoniste du recepteur ppar
CA2497901A1 (en) * 2002-09-06 2004-03-18 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
US7691905B2 (en) * 2002-12-24 2010-04-06 New York University Inhibition of melanogenesis and melanoma metastasis with p-aminobenzoic acid (PABA)
WO2006066894A1 (en) * 2004-12-24 2006-06-29 Ctg Pharma S.R.L. Compounds for treating metabolic syndrome
KR20050119648A (ko) * 2003-03-13 2005-12-21 오노 야꾸힝 고교 가부시키가이샤 이미노 에테르 유도체 화합물 및 그 화합물을 유효성분으로서 함유하는 약제
EP1457485A1 (en) 2003-03-14 2004-09-15 Dompé S.P.A. Sulfonic acids, their derivatives and pharmaceutical compositions containing them
ES2222831B2 (es) * 2003-07-30 2006-02-16 Laboratorios Del Dr. Esteve, S.A. Combinacion de principio activo que comprende un compuesto 2,5-dihidroxibencenosulfonico y un modulador de los canales de k+.
AR046330A1 (es) * 2003-09-09 2005-12-07 Japan Tobacco Inc Inhibidor de dipeptidilpeptidasa iv
GB0321228D0 (en) * 2003-09-10 2003-10-08 Inpharmatica Ltd Modulating cell activity
US20050175559A1 (en) 2004-02-10 2005-08-11 Pcr Technology Holdings, Lc Method and preparation for reducing skin hyperpigmentation
US20070149618A1 (en) * 2004-02-17 2007-06-28 Action Medicines, S.L. Methods of use for 2,5-dihydroxybenzene sulfonic acid compounds for the treatment of cancer, rosacea and psoriasis
ES2238924B1 (es) 2004-02-17 2006-12-01 Investread Europa, S.L. Uso del acido 2,5-dihidroxibencenosulfonico, en la fabricacion de medicamentos de aplicacion en el tratamiento de enfermedades angiodependientes.
DE602004026647D1 (de) 2004-09-14 2010-05-27 Ajinomoto Omnichem S A Topische zusammensetzungen mit phosphorylierten polyphenolen
EP1676573A1 (en) 2004-12-30 2006-07-05 Laboratorios Del Dr. Esteve, S.A. Phamaceutical composition comprising a 2,5-dihydroxybenzenesulfonic-compound, a potassium ion channel modulator and a phosphodiesterase type 5 inhibitor
JP4862277B2 (ja) * 2005-05-10 2012-01-25 三菱自動車工業株式会社 電池
EP1749820A1 (en) * 2005-07-15 2007-02-07 Laboratorios Del Dr. Esteve, S.A. Salts of substituted pyrazoline compounds, their preparation and use as medicaments
KR20080031936A (ko) * 2005-08-04 2008-04-11 노파르티스 아게 빌다글립틴의 염
CN1768769A (zh) * 2005-09-22 2006-05-10 关海山 克疣
US8541467B2 (en) * 2006-08-16 2013-09-24 Action Medicines, S.L. Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of hematological dyscrasias and cancer of an organ
US20080114075A1 (en) * 2006-08-16 2008-05-15 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Dermatitis

Also Published As

Publication number Publication date
WO2008020025A1 (en) 2008-02-21
ES2413855T3 (es) 2013-07-17
AR062398A1 (es) 2008-11-05
EP2054051B1 (en) 2013-02-27
US20180036265A1 (en) 2018-02-08
US20160008303A1 (en) 2016-01-14
CL2007002380A1 (es) 2008-01-18
EP2054051A1 (en) 2009-05-06
EP2056815B1 (en) 2013-03-20
US10434076B2 (en) 2019-10-08
PT2054051E (pt) 2013-04-03
US9597303B2 (en) 2017-03-21
US20080114075A1 (en) 2008-05-15
ES2409172T3 (es) 2013-06-25
US20140328778A1 (en) 2014-11-06
CL2007002389A1 (es) 2008-01-18
US20120087947A1 (en) 2012-04-12
WO2008020037A1 (en) 2008-02-21
WO2008020026A1 (en) 2008-02-21
PT2056815E (pt) 2013-04-03
CL2007002381A1 (es) 2008-01-18
AR062401A1 (es) 2008-11-05
US9192592B2 (en) 2015-11-24
US8815836B2 (en) 2014-08-26
EP2056815A1 (en) 2009-05-13

Similar Documents

Publication Publication Date Title
AR062400A1 (es) Uso de derivados de 2,5-dihidroxibenceno para tratar queratosis actinica
ES2430204T3 (es) Uso de compuestos de 2,5-dihidroxibenceno y sus derivados para el tratamiento de la rosácea
PE20050822A1 (es) Derivados de florfenicol con mejor solubilidad en agua
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
AR080974A1 (es) Derivados piridinicos y piperazinicos moduladores de la actividad de los canales del calcio activado por depositos intracelulares(soc), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y trastornos inmunes, entre otras.
GT200000170A (es) Agentes terapeuticos.
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
AR064561A1 (es) Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
AR047966A1 (es) Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico
CR9022A (es) Derivados de sulfonamida novedosos como moduladores de receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
NI201800051A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso en eltratamiento de cáncer
DOP2005000006A (es) "derivados de sulfonamida para el tratamiento de enfermedades"
AR054188A1 (es) Aminas ciclicas con actividad inhibitoria del factor de coagulacion xa, metodos para su sintesis, intermediarios del proceso de obtencion de las mismas y su elaboracion, composiciones farmaceuticas que las contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades del a
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
AR051797A1 (es) Derivados de hidantoina inhibidores de metaloproteinasas
BR112014005546A2 (pt) ácidos graxos ômega para tratamento de doenças
AR062399A1 (es) Uso de derivados del 2,5-dihidroxibenceno para el tratamiento de enfermedades de reaccion a tejido
AR057909A1 (es) Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
AR064702A1 (es) Agonistas de receptores de proteina g heterociclicos, una composicion farmaceutica que los comprende y su uso en el tratamiento de la diabetes y trastornos metabolicos.
BR0311363A (pt) Formulação farmacêutica de liberação imediata, uso da mesma, e, método para tratar um distúrbio cardiovascular em um paciente
BR112014004732A2 (pt) composto benzotiazolona
AR073089A1 (es) DERIVADOS DE (POLI)AMINOALQUILAMINOALQUILAMIDAS, ALQUIL-UREA O ALQUILSULFONAMIDA DE EPIPODOFILOTOXINA, UN PROCESO PARA PREPARARLOS, SU APLICACIoN EN TERAPIA COMO AGENTES ANTICANCER Y COMPOSICION FARMACEUTICA QUE LOS CONTIENEN.
CO2024002844A2 (es) Compuestos espirocíclicos
ES2478447T3 (es) Formulaciones del ácido desoxicólico y sus sales

Legal Events

Date Code Title Description
FB Suspension of granting procedure